{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to study procedures and their timing from Section 9"
      },
      {
        "id": "ref_2",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to laboratory tests from Section 9 and Schedule of Activities"
      },
      {
        "id": "ref_3",
        "name": "Blood Sampling Summary Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference to maximum number and volume of invasive samples from Section 9"
      },
      {
        "id": "ref_4",
        "name": "Treatment Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference to treatment details from Section 9.2.2"
      },
      {
        "id": "ref_5",
        "name": "Nasal and Non-nasal Score Questionnaire Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference to questionnaire from Section 9.2.2.1 and 9.3.1.2"
      },
      {
        "id": "ref_6",
        "name": "Edinburgh Hypoglycemia Scale Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference to hypoglycemia assessment tool from Section 9.1.3 and 9.3.1.2"
      },
      {
        "id": "ref_7",
        "name": "Clarke Hypoglycemia Awareness Survey Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference to self-report assessment from Section 9.1.3"
      },
      {
        "id": "ref_8",
        "name": "Hepatic Monitoring Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference to liver tests from Section 9.5.5.2"
      },
      {
        "id": "ref_9",
        "name": "Protocol Amendment Summary Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 9",
        "sectionTitle": "Protocol Amendment I8R-JE-IGBJ(a) Summary",
        "description": "Reference to amendment summary for Phase 3 Study"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_2",
        "text": "When needed to confirm postmenopausal status.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - FSH Testing",
        "pageNumber": 15
      },
      {
        "id": "annot_3",
        "text": "Additional tests can be done at the discretion of the investigator.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Ethanol Testing",
        "pageNumber": 15
      },
      {
        "id": "annot_4",
        "text": "This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_5",
        "text": "In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "a",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol Amendment (a) Electronically Signed and Approved by Lilly",
        "amendmentNumber": "Amendment (a)"
      },
      {
        "id": "ver_2",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-10-26",
        "description": "Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 5,
      "versionCount": 2
    }
  }
}